Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Sangamo Therapeutics's free cash flow for the twelve months ending Mar 31, 2026 was -$90.46M. For fiscal 2025 it was -$97.31M. The highest annual figure on record is $155.16M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$97.31M | – |
| FY2024 | Dec 31, 2024 | -$67.41M | – |
| FY2023 | Dec 31, 2023 | -$246.00M | – |
| FY2022 | Dec 31, 2022 | -$243.80M | – |
| FY2021 | Dec 31, 2021 | -$256.53M | -265.3% |
| FY2020 | Dec 31, 2020 | $155.16M | – |
| FY2019 | Dec 31, 2019 | -$165.08M | – |
| FY2018 | Dec 31, 2018 | -$6.52M | -187.7% |
| FY2017 | Dec 31, 2017 | $7.43M | – |
| FY2016 | Dec 31, 2016 | -$66.62M | – |
| FY2015 | Dec 31, 2015 | -$36.13M | – |
| FY2014 | Dec 31, 2014 | -$6.30M | – |
| FY2013 | Dec 31, 2013 | -$19.91M | – |
| FY2012 | Dec 31, 2012 | -$8.81M | – |
| FY2011 | Dec 31, 2011 | -$26.47M | – |
| FY2010 | Dec 31, 2010 | -$24.63M | – |
| FY2009 | Dec 31, 2009 | -$6.41M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$19.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$24.42M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.56M | -345.3% |
| Q2 FY2025 | Jun 30, 2025 | -$18.18M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.15M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.50M | – |
| Q3 FY2024 | Sep 30, 2024 | $11.64M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.88M | – |
| Q1 FY2024 | Mar 31, 2024 | -$48.66M | – |
| Q4 FY2023 | Dec 31, 2023 | -$53.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$50.04M | – |
| Q2 FY2023 | Jun 30, 2023 | -$66.25M | – |
| Q1 FY2023 | Mar 31, 2023 | -$76.50M | – |
| Q4 FY2022 | Dec 31, 2022 | -$64.52M | – |
| Q3 FY2022 | Sep 30, 2022 | -$58.03M | – |
| Q2 FY2022 | Jun 30, 2022 | -$59.43M | – |
| Q1 FY2022 | Mar 31, 2022 | -$61.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$55.57M | – |
| Q3 FY2021 | Sep 30, 2021 | -$64.63M | -322.4% |
| Q2 FY2021 | Jun 30, 2021 | -$59.83M | -138.1% |
| Q1 FY2021 | Mar 31, 2021 | -$76.50M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.31M | – |
| Q3 FY2020 | Sep 30, 2020 | $29.06M | – |
| Q2 FY2020 | Jun 30, 2020 | $157.07M | – |
| Q1 FY2020 | Mar 31, 2020 | -$22.67M | – |
| Q4 FY2019 | Dec 31, 2019 | -$27.60M | – |
| Q3 FY2019 | Sep 30, 2019 | -$43.01M | – |
| Q2 FY2019 | Jun 30, 2019 | -$43.38M | -136.4% |
| Q1 FY2019 | Mar 31, 2019 | -$51.10M | – |
| Q4 FY2018 | Dec 31, 2018 | -$68.20M | – |
| Q3 FY2018 | Sep 30, 2018 | -$36.86M | – |
| Q2 FY2018 | Jun 30, 2018 | $119.29M | +116.6% |
| Q1 FY2018 | Mar 31, 2018 | -$20.75M | – |
| Q4 FY2017 | Dec 31, 2017 | -$17.72M | – |
| Q3 FY2017 | Sep 30, 2017 | -$16.39M | – |
| Q2 FY2017 | Jun 30, 2017 | $55.08M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.55M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.99M | – |
| Q3 FY2016 | Sep 30, 2016 | -$17.73M | – |
| Q2 FY2016 | Jun 30, 2016 | -$16.28M | – |
See a number that looks wrong?